Smart Stop: A Phase II Trial of Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Prior to and With Standard Chemotherapy for Patients With Newly Diagnosed DLBCL
Latest Information Update: 10 Dec 2024
Price :
$35 *
At a glance
- Drugs Acalabrutinib (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Lenalidomide (Primary) ; Prednisone (Primary) ; Rituximab (Primary) ; Tafasitamab (Primary) ; Vincristine (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms Smart Stop
- 06 Dec 2024 Planned End Date changed from 16 Jan 2025 to 16 Jan 2027.
- 06 Dec 2024 Planned primary completion date changed from 16 Jan 2025 to 16 Jan 2027.
- 12 Dec 2023 Preplanned interim results from from cohort 1, presented at the 65th American Society of Hematology Annual Meeting and Exposition